Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines–Heart Failure (GWTG-HF) Registry

IMPORTANCE: In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) tr...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:JAMA Cardiol
Główni autorzy: Vaduganathan, Muthiah, Greene, Stephen J., Zhang, Shuaiqi, Grau-Sepulveda, Maria, DeVore, Adam D., Butler, Javed, Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., Fonarow, Gregg C.
Format: Artigo
Język:Inglês
Wydane: American Medical Association 2020
Hasła przedmiotowe:
Original Investigation
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666432/
https://ncbi.nlm.nih.gov/pubmed/33185662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.5864
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy